Immuno-Oncology Panel Session
Kineticos recently tapped 3 industry veterans and Oncology experts to participate in a panel to discuss where we are today in terms of the Immuno-Oncology treatment landscape and what the future holds. The first installment was focused on the overall treatment paradigm and our second installment examines what these breakthrough therapies mean to patients who want access to the best and most precise therapies for their diseases.
- Chris Heery – Chief Medical Officer, Bavarian Nordic
- Jeff Kmetz – Former Chief Business Officer, Pulse Biosciences
- Alex Dusek – Vice President of Commercial Strategy, Erytech (To be featured in Parts 2-4)
Click here for a condensed and edited version of Part 2.
Subscribe to Kineticos and receive more insightful content.